全文获取类型
收费全文 | 3506篇 |
免费 | 182篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 166篇 |
妇产科学 | 150篇 |
基础医学 | 411篇 |
口腔科学 | 85篇 |
临床医学 | 273篇 |
内科学 | 1089篇 |
皮肤病学 | 89篇 |
神经病学 | 161篇 |
特种医学 | 120篇 |
外科学 | 373篇 |
综合类 | 41篇 |
一般理论 | 1篇 |
预防医学 | 163篇 |
眼科学 | 46篇 |
药学 | 291篇 |
中国医学 | 12篇 |
肿瘤学 | 193篇 |
出版年
2021年 | 49篇 |
2020年 | 36篇 |
2019年 | 37篇 |
2018年 | 54篇 |
2017年 | 42篇 |
2016年 | 40篇 |
2015年 | 46篇 |
2014年 | 70篇 |
2013年 | 97篇 |
2012年 | 149篇 |
2011年 | 158篇 |
2010年 | 108篇 |
2009年 | 87篇 |
2008年 | 140篇 |
2007年 | 145篇 |
2006年 | 130篇 |
2005年 | 143篇 |
2004年 | 159篇 |
2003年 | 132篇 |
2002年 | 134篇 |
2001年 | 141篇 |
2000年 | 175篇 |
1999年 | 120篇 |
1998年 | 31篇 |
1997年 | 38篇 |
1996年 | 30篇 |
1995年 | 26篇 |
1994年 | 19篇 |
1993年 | 23篇 |
1992年 | 105篇 |
1991年 | 95篇 |
1990年 | 67篇 |
1989年 | 77篇 |
1988年 | 77篇 |
1987年 | 73篇 |
1986年 | 69篇 |
1985年 | 78篇 |
1984年 | 65篇 |
1983年 | 51篇 |
1982年 | 20篇 |
1981年 | 26篇 |
1980年 | 17篇 |
1979年 | 39篇 |
1978年 | 28篇 |
1977年 | 20篇 |
1975年 | 25篇 |
1974年 | 24篇 |
1973年 | 23篇 |
1972年 | 20篇 |
1970年 | 14篇 |
排序方式: 共有3694条查询结果,搜索用时 171 毫秒
1.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
2.
Manish Gautam Santanu Saha Sarang Bani A. Kaul Sanjay Mishra Dada Patil N.K. Satti K.A. Suri Sunil Gairola K. Suresh Suresh Jadhav G.N. Qazi Bhushan Patwardhan 《Journal of ethnopharmacology》2009
Ethnopharmacological relevance
Roots of Asparagus racemosus Willd (Shatavari in vernacular) are widely used in Ayurveda as Rasayana for immunostimulation, galactogogue as also in treatment of conditions like ulcers and cancer. Various studies have indicated immunomodulatory properties of Shatavari root extracts and formulations.Aim of the study
To study the effect of standardized Asparagus racemosus root aqueous extract (ARE) on systemic Th1/Th2 immunity of SRBC sensitized animals.Materials and methods
We used HPTLC to quantify steroidal saponins (Shatavarin IV, Immunoside®) and flow cytometry to study effects of ARE on Th1/Th2 immunity. SRBC specific antibody titres and DTH responses were also monitored as markers of Th2 and Th1 responses, respectively. We also studied lymphocyte proliferation. Cyclosporin, cyclophosphamide and levamisole were used as controls.Results
Treatment with ARE (100 mg/(kg b.w. p.o.)) resulted in significant increase of CD3+ and CD4/CD8+ percentages suggesting its effect on T cell activation. ARE treated animals showed significant up-regulation of Th1 (IL-2, IFN-g) and Th2 (IL-4) cytokines suggesting its mixed Th1/Th2 adjuvant activity. Consistent to this, ARE also showed higher antibody titres and DTH responses. ARE, in combination with LPS, Con A or SRBC, produced a significant proliferation suggesting effect on activated lymphocytes.Conclusion
The study suggests mixed Th1/Th2 activity of ARE supports its immunoadjuvant potential. 相似文献3.
4.
Insights into the assessment of myocardial perfusion offered by different cardiac imaging modalities
Myocardial perfusion may be very broadly defined as the tightly regulated nutrient delivery to cardiac tissue. The different
components of perfusion are myocardial blood flow, oxygen delivery, myocardial oxygen consumption, and myocardial blood volume.
Historically, focus has been placed mostly on the assessment of blood flow. In many instances, knowledge of flow without information
about these other aspects is inadequate. This review discusses the various cardiac imaging techniques used for the assessment
of myocardial perfusion that represent diverse physiologic measures of “perfusion.” Their strengths and limitations are discussed
as is their relevance to specific clinicopathologic conditions. Significant work still needs to be performed before all the
aspects of myocardial perfusion can be precisely measured in human beings.
Supported in part by a grant (R01-HL48890) from the National Institutes of Health, Bethesda, Md. Dr. Lindner is the recipient
of a Fellowship Training Grant from the Virginia Affiliate of the American Heart Association, Glen Allen, Va. Dr. Kaul is
an Established Investigator of the National Center of the American Heart Association, Dallas, Texas. 相似文献
5.
6.
7.
J Uusi-Simola T Serén T Sepp?l? A Kosunen I Auterinen S Savolainen 《Applied radiation and isotopes》2004,61(5):845-848
Tissue equivalent proportional counter microdosimetry has been applied in the dosimetry of epithermal neutron beams as they can provide an independent and accurate method to determine gamma ray and neutron absorbed doses. Dosimetric comparison has been performed using a tissue equivalent proportional counter, dual ionisation chambers and DORT computer code at FiR 1 boron neutron capture therapy facility in Espoo, Finland. The three methods were applied to determine neutron and gamma ray absorbed doses at 25, 40, 60 and 120 mm depths along the beam centerline in a water-filled PMMA phantom. The determined absorbed doses were found to agree within the limits of the estimated uncertainties. 相似文献
8.
D. Le Elizabeth Eric R. Powers Jian-Ping Bin Howard Leong-Poi N. Craig Goodman Sanjiv Kaul 《Journal of nuclear cardiology》2007,14(2):207-214
Background The mechanism by which transmyocardial revascularization (TMR) offers clinical benefit is controversial. We hypothesized that
TMR ameliorates ischemia by reversing paradoxical catecholamine-induced vasoconstriction.
Methods and Results Chronic ischemic cardiomyopathy was created in 11 dogs by placing ameroid constrictors on the proximal coronary arteries and
their major branches. Six weeks later, 35 channels were created percutaneously in the left circumflex artery region, with
the left anterior descending artery region serving as control. At rest, wall thickening and myocardial blood flow did not
change in the treated region, whereas they deteriorated in the control bed. Contractile and myocardial blood flow reserve
increased in the treated region but deteriorated in the control region. There was diminished iodine 123 metaiodobenzylguanidine
uptake and a significant reduction in noradrenergic nerves in the treated region compared with the control region, with a
corresponding reduction in tissue tyrosine hydroxylase activity.
Conclusions We conclude that the absence of a catecholamine-induced reduction in MBF reserve and contractile reserve in the TMR-treated
region with associated evidence of neuronal injury indicates that the relief of exercise-induced ischemia after TMR most likely
results from reversal of paradoxical catecholamine-induced vasoconstriction. These findings may have implications in selecting
patients who would benefit from TMR.
Supported in part by grants from the National Institutes of Health (R01-HL66034 and K-08-HL074290-01). Bethesda. Md. The radio-labeled
microspheres were provided by DuPont Pharmaceuticals, North Billerica. Mass, and the ultrasound equipment was supplied by
Philips. Andover, Mass. Dr Leong-Poi was the recipient of a Fellowship Training Grant from the Canadian Institute of Health
Research and the Heart and Stroke Foundation of Canada. 相似文献
9.
This case report documents the first patient from main land China with an HTLV-1-associated myelopathy. The available epidemiological data suggest a low rate of HTLV 1 infection in China, although the surveys are comparatively small. Possible transmission routes and the risk of encountering the disease outside endemic areas are discussed. 相似文献
10.
We compared the antihypertensive effects and tolerability of a new calcium channel antagonist felodipine with nifedipine in an open randomised parallel group study in 49 patients with moderate hypertension (diastolic blood pressure 105-120 mm Hg). After two weeks run in period felodipine 5 mg and 10 mg once daily was compared with nifedipine 10 mg tid for an active treatment period of 4 weeks. Twenty three patients (mean age 42 +/- 10 years) received felodipine 5 mg once daily for first 2 weeks and 10 mg once daily for subsequent 2 weeks. Twenty six patients (mean age 45 +/- 9 years) received nifedipine 10 mg tid for 4 weeks. The mean reduction in supine diastolic blood pressure in two groups was 17 +/- 6 mm Hg (nifedipine) and 19 +/- 8 mm Hg (felodipine) (p = NS). The goal diastolic blood pressure of less than or equal to 90 mm Hg was achieved in 31 percent (nifedipine group) and 43.5 percent (felodipine group) of patients (p = NS). Side effects were common with both drugs; however, the tolerability was better with felodipine than with nifedipine. In conclusion felodipine was as effective as nifedipine and had the advantage of once a day dosage. 相似文献